Study #ALLIANCEA151216
ALLIANCEA151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) - Genetic Testing for Patients with Resectable or Resected Lung Cancer
MD Anderson Study Status
Enrolling
Treatment Agent
Erlotinib, Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pemetrexed, Pemetrexed Disodium, Pembrolizumab, Crizotinib, Nivolumab
Description
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
Study phase:
Not applicable
Physician name:
Mara Antonoff
Department:
Thoracic & Cardiovascular Surgery
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.